相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Yang Cao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)
RNA splicing dysregulation and the hallmarks of cancer
Robert K. Bradley et al.
NATURE REVIEWS CANCER (2023)
High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
Emanuela M. Ghia et al.
LEUKEMIA (2022)
Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.
Stephen J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E. Budde et al.
LANCET ONCOLOGY (2022)
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells
Scarlett Y Yang et al.
Blood Advances (2022)
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
Sisi Zheng et al.
BLOOD CANCER DISCOVERY (2022)
CD20 as a gatekeeper of the resting state of human B cells
Kathrin Klaesener et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Disrupting upstream translation in mRNAs is associated with human disease
David S. M. Lee et al.
NATURE COMMUNICATIONS (2021)
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib
Veronika Sandova et al.
HAEMATOLOGICA (2021)
Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts
Laura Schulz et al.
GENOME BIOLOGY (2021)
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19
Mukta Asnani et al.
LEUKEMIA (2020)
The regulation and function of CD20: an enigma of B-cell biology and targeted therapy
Gabriela Pavlasova et al.
HAEMATOLOGICA (2020)
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Christopher K. Rushton et al.
BLOOD ADVANCES (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children
Veronique Minard-Colin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing
Sara Parsa et al.
NATURE CANCER (2020)
Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent
Sara E. Bodbin et al.
METHODS AND PROTOCOLS (2020)
ComBat-seq: batch effect adjustment for RNA-seq count data
Yuqing Zhang et al.
NAR GENOMICS AND BIOINFORMATICS (2020)
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Eric Wang et al.
CANCER CELL (2019)
RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types
Gianni Monaco et al.
CELL REPORTS (2019)
Novel AU-rich proximal UTR sequences (APS) enhance CXCL8 synthesis upon the induction of rpS6 phosphorylation
Zhiwei Ang et al.
PLOS GENETICS (2019)
Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection
Paulina Mrozek-Gorska et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies
Pedro Horna et al.
BLOOD (2019)
TPMCalculator: one-step software to quantify mRNA abundance of genomic features
Roberto Vera Alvarez et al.
BIOINFORMATICS (2019)
Global distribution of DNA hydroxymethylation and DNA methylation in chronic lymphocytic leukemia
Sara Wernig-Zorc et al.
EPIGENETICS & CHROMATIN (2019)
Escape From ALL-CARTaz Leukemia Immunoediting in the Age of Chimeric Antigen Receptors
Sisi Zheng et al.
CANCER JOURNAL (2019)
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars
Jennifer R. Brown et al.
ONCOLOGIST (2018)
TSVdb: a web-tool for TCGA splicing variants analysis
Wenjie Sun et al.
BMC GENOMICS (2018)
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
Beata Pyrzynska et al.
ONCOIMMUNOLOGY (2018)
Past, Present, and Future of Rituximab-The world's First Oncology Monoclonal Antibody Therapy
Timothy M. Pierpont et al.
FRONTIERS IN ONCOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma
Hui Yu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences
Yasin Kaymaz et al.
MOLECULAR CANCER RESEARCH (2017)
Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2017)
On Essentiality and the World Health Organization's Model List of Essential Medicines
Victoria A. Marks et al.
ANNALS OF GLOBAL HEALTH (2017)
Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients
Anant A. Agrawal et al.
BLOOD ADVANCES (2017)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S. Nowakowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
Xue-hai Liang et al.
NATURE BIOTECHNOLOGY (2016)
Therapeutic targeting of splicing in cancer
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Sebastien Maury et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
Ha Young Park et al.
ONCOTARGET (2016)
Tunable protein synthesis by transcript isoforms in human cells
Stephen N. Floor et al.
ELIFE (2016)
A new view of transcriptome complexity and regulation through the lens of local splicing variations
Jorge Vaquero-Garcia et al.
ELIFE (2016)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S. Nowakowski et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab
Gregory A. Rufener et al.
CANCER IMMUNOLOGY RESEARCH (2016)
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies
Clementine Gamonet et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
Enhancer Sequence Variants and Transcription-Factor Deregulation Synergize to Construct Pathogenic Regulatory Circuits in B-Cell Lymphoma
Olivia I. Koues et al.
IMMUNITY (2015)
Cutting Edge: Redox Signaling Hypersensitivity Distinguishes Human Germinal Center B Cells
Hannah G. Polikowsky et al.
JOURNAL OF IMMUNOLOGY (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma
Francesco Abate et al.
PLOS PATHOGENS (2015)
MXS-Chaining: A Highly Efficient Cloning Platform for Imaging and Flow Cytometry Approaches in Mammalian Systems
Hanna L. Sladitschek et al.
PLOS ONE (2015)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop
James N. Psathas et al.
BLOOD (2013)
Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
Lihua E. Budde et al.
PLOS ONE (2013)
Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment
Hiroaki Miyoshi et al.
CANCER SCIENCE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
ViennaRNA Package 2.0
Ronny Lorenz et al.
ALGORITHMS FOR MOLECULAR BIOLOGY (2011)
Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance
Carole Henry et al.
BLOOD (2010)
Modulation of CD20 Antigen Expression After Rituximab Treatment: A Retrospective Study in Patients With Chronic Lymphocytic Leukemia
Fiorella D'Auria et al.
CLINICAL THERAPEUTICS (2010)
Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect
Shannon M. Sarro et al.
LEUKEMIA RESEARCH (2010)
SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans
Francesco Piva et al.
BIOINFORMATICS (2009)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Nathalie A. Johnson et al.
BLOOD (2009)
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
Nathalie A. Johnson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues
Paul A. Morcos et al.
BIOTECHNIQUES (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos
Paul A. Morcos
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
Sima Jeha et al.
BLOOD (2006)
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry
SH Olejniczak et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms
W Wojciechowski et al.
JOURNAL OF IMMUNOLOGY (2005)
Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: Implications for adjuvant therapies
DN Yu et al.
CANCER RESEARCH (2005)
Loss of CD20 expression in relapsed lymphomas after rituximab therapy
JH Haidar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Comparative analysis of light chain expression in germinal center cells and mantle cells of reactive lymphoid tissues - A four-color flow cytometric study
KK Reichard et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Identification of cellular mRNA targets for RNA-binding protein Sam68
M Itoh et al.
NUCLEIC ACIDS RESEARCH (2002)
Rituximab:: Ongoing and future clinical development
AJ Grillo-López et al.
SEMINARS IN ONCOLOGY (2002)
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia
J Perz et al.
LEUKEMIA & LYMPHOMA (2002)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Upstream open reading frames as regulators of mRNA translation
DR Morris et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
